Empowering New Zealand Nurses for Excellence in Healthcare
Bicultural Structure
Membership includes belonging to a bicultural organisation focused on professional nursing issues and community health.
Insurance Coverage
Members receive up to $1 million indemnity insurance in New Zealand (not applicable for retired members). (Conditions apply).
Access to Publications
Members have access to the ‘Nursing Praxis in Aotearoa New Zealand’ journal.
Influence and Networking
Members contribute to a significant influencer in health policy decision-making and join a dynamic network of professional nurses committed to high standards of practice.
9 June 2026
Pharmac Notification
From 1 July 2026, Pharmac will take over responsibility for funding medicines used in ambulances. This decision outlines changes to the Pharmaceutical Schedule to support this change in responsibility. Under this decision, we will also fund tenecteplase for use within emergency ambulance services and Primary Responses in Medical Emergencies (PRIME) services. We want to make sure that everyone who needs to know about this decision is aware of it. Please share this information with people you...
9 June 2026
Pharmac Consultation
Pharmac is seeking feedback on a proposal to change the funded brand of dapsone tablets, which are currently supplied by Link Pharmaceuticals (Dapsone). We are also seeking feedback on a related change to remove the 25 mg tablet from the Pharmaceutical Schedule due to its discontinuation and replace it with a 50 mg (scored / halveable) tablet. A 100 mg tablet will remain available, but its brand would change. Proposal for the supply of dapsone tablets No changes are proposed to the current...
8 June 2026
Pharmac - Supply Update
New medicine supply notices Reandron testosterone is changing brand to Gonadron Gonadron will be listed from 1 July. Reandron will remain funded until 1 December. Information (including pictures) is available on the website for affected people. Valaciclovir (Vaclovir) 1,000 mg (Pharmacode: 2483912) Stock of this product will run out. Two s29 alternatives have been listed. Please use the funded alternatives rather than 2 x 500 mg to avoid a supply issue affecting the lower dose. Updated...
8 June 2026
Pharmac Update: Primary Care Prescribers | 05 June 2026
Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 05 June 2026. It includes information on: New updates Resolved Supply Issues Supply disruption: Colestyramine Powder for Oral Suspension (Sachet) There is a supply disruption affecting the currently listed colestyramine oral sachets, Colestyramine – Mylan S29. From 1 June, Pharmac listed (funded) an alternative Section 29 product: Questran Light (neon). Questran...
4 June 2026
Nurse Practitioner Rural Health - Hawera
Based at Hāwera Hospital Permanent, full-time or part-time role Play a pivotal role in rural health Health New Zealand | Te Whatu Ora is firmly grounded in the principles of Te Tiriti o Waitangi and is committed to building a health system that serves all New Zealanders. About the role Mātanga tapuhi (Nurse Practitioners) and Nurse Practitioner Interns have advanced education, clinical training, and the demonstrated competence and legal authority to practise beyond the level of a registered...
2 June 2026
Nurse Practitioner - North Shore, Auckland
Nurse Practitioner – North Shore, Auckland No weekends | Flexible hours | Supportive team Join a well‑established general practice on Auckland’s North Shore. Work in a friendly, collaborative environment with excellent work–life balance. The Role Provide patient-centred care across acute, chronic, and preventive health needs in a supportive primary care setting. What We Offer No weekends or public holidaysFlexible hours. Established patient baseSupportive clinical and admin teamModern...
2 June 2026
Registered Nurse - Auckland
Te Wairua (co-existing disorders – addictions + mental health) residential service in Royal Oak, great benefits and competitive salary package! Mon-Fri $78,020 - $86,174 salary (depending on experience) $7,000 annual position allowance + free meals + 22 days annual leave Monday to Friday, no evenings, no weekends! Registered Nurse – Te Wairua Royal Oak If you would like to make a positive difference and use your experience as a registered nurse, then join our Te Wairua (co-existing...
2 June 2026
New medicine supply notices
Colestyramine (Mylan) (Pharmacode: 2662000) Supplies may be limited from late May until July 2026. An alternative (Pharmacode: 2700026) was funded from 1 June and should be available from Orspec in early June. Kisqali (ribociclib): Storage changes Kisqali will once again be able to be stored at room temperature. More details and a flyer for patients are available on our website. Neocate Gold: Funding issue The Pharmacode for new look Neocate Gold was funded from 1 June. Oestradiol valerate...
1 June 2026
Ministry of Health - Medical Products & Natural Health Products Update
Welcome to the latest update from the Ministry of Health | Manatū Hauora on the regulation of medicines, medical devices and natural health products. This edition provides information on the Government’s recent decision to regulate sunscreens and other policy matters under the Medical Products Bill (the Bill). This update also accompanies the proactive release of documents relating to those decisions. This newsletter contains information on the following: New policy decisions for the Bill · ...
29 May 2026
Supply Issue – Risperidone (Teva) 0.5mg tablets and Risperidone (Teva) 2mg tablets
There is currently a supply disruption affecting risperidone (Teva) 0.5 mg and 2 mg tablets. This is due to an issue at the manufacturer. To support continuity of care, from 1 June, Pharmac will list (fund) alternative products, Risperidone Sandoz 0.5 mg tab and Risperidone Sandoz 2 mg tab. Please note Risperidone Sandoz tablets are not Medsafe‑approved and must therefore be prescribed and supplied in accordance with Section 29A of the Medicines Act. Further information about this...
29 May 2026
Supply disruption: Colestyramine Powder for Oral Suspension (Sachet)
Re: Supply disruption: Colestyramine Powder for Oral Suspension (Sachet). There is a supply disruption affecting the currently listed Section 29 colestyramine oral sachets, Colestyramine – Mylan. From 1 June, Pharmac will list an alternative Section 29 product: Questran Light (Neon). This is not a Medsafe‑approved product and must be prescribed in accordance with Section 29 of the Medicines Act. As no Medsafe approved product is currently listed on the Schedule, Section 29A does not...
29 May 2026
Pharmac Update: Primary Care Prescribers | 29 May 2026
Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 29 May 2026. It includes information on: New updates Resolved Supply Issues Supply Constraint – TruSteel Infusion Sets There is a global supply constraint affecting TruSteel infusion sets due to issues at a component supplier. This disruption is not specific to New Zealand and is likely to continue for the rest of 2026. It affects all four funded TruSteel infusion...
29 May 2026
Ministry of Health Library - Health Improvemtn & Innovation Digest
Issue 343 - 28 May 2026 Welcome to the fortnightly Health Improvement and Innovation Digest. The Digest has links to key evidence of interest, with access to new content arranged by topic. You can forward this newsletter to others who may be interested in receiving it. They can register and subscribe here. You can also access other recent issues of the digest here. If you have any queries, please email us at library@health.govt.nz. Article Access For articles that aren't open access, contact...
29 May 2026
Lowering LDL to <1.4 mmol/L reduces events in known CVD
Evidence from randomised trials on optimal LDL cholesterol targets for secondary prevention in known atherosclerotic cardiovascular disease is limited. In an open trial, 3048 patients with known CVD disease were randomised to an LDL target of below 1.4 mmol/L or below 1.8 mmol/L.1 The primary outcome was a composite of cardiovascular death, nonfatal myocardial infarction or stroke, revascularisation, or hospitalisation for unstable angina over 3 years. The median achieved LDL levels were 1.4...
29 May 2026
Pharmac Consultation
We’re writing to let you know that Pharmac is extending the consultation period on the proposed changes to access criteria for type 2 diabetes medicines. In May, we released a proposal to amend the Special Authority criteria for empagliflozin, liraglutide, and dulaglutide. We’ve received a significant amount of feedback so far, which reflects how important access to these medicines is for people living with type 2 diabetes. We’ve also heard that more people would like the opportunity to...
25 May 2026
New medicine supply notices
New medicine supply notices Fluorouracil inj 50 mg/ml 20 ml and 50 ml vials: (Pharmacodes: 2618435 and 2674092) Accord is out of stock of these products. Paracetamol oral liquid: Lower strength (120 mg per 5 ml)The brand of this product is changing brand from 1 June 2026. Updated medicine supply notices Droperidol inj 2.5 mg per ml, 1 ml ampoule (Pharmacode 2690543) The previously funded brand, PanPharma (Pharmacode:2527138), has been re-listed. There is a small amount of this stock...
25 May 2026
DATE CORRECTION - Testosterone (Reandron) Injection
This is to correct the dates sent out on Friday. Gonadron brand will be listed 1 July 2026 Brand change: We are writing to inform you of a brand change for testosterone undecanoate inj 250 mg per ml, (Reandron) Key Dates: The Gonadron brand of testosterone undecanoate inj 250 mg per ml is to be listed (funded) from 1 July 2026 on the Community Schedule and in Health NZ hospitals. Testosterone undecanoate inj 250 mg per ml (Reandron) brand will be delisted (no longer funded) 1 December...
24 May 2026
Pharmac Update: Primary Care Prescribers | 22 May 2026
Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 22 May 2026. It includes information on: New updates Resolved Supply Issues Supply Disruption - Ezetimibe with Simvastatin 10/80 mg (Zimybe) Due to a delay at the manufacturing site, there is a supply issue affecting ezetimibe with simvastatin 10/80 mg combination tablet (Zimybe). From 1 June 2026 Pharmac is funding an alternative product ezetimibe with simvastatin...
24 May 2026
Brand Change: testosterone undecanoate inj 250 mg per ml, (Reandron) to new brand (Gonadron)
Brand change: We are writing to inform you of a brand change for testosterone undecanoate inj 250 mg per ml, (Reandron) Key Dates: The Gonadron brand of testosterone undecanoate inj 250 mg per ml is to be listed (funded) from 1 June 2026 on the Community Schedule and in Health NZ hospitals. Testosterone undecanoate inj 250 mg per ml (Reandron) brand will be delisted (no longer funded) 1 November 2026. The active ingredients and excipients are the same as the Reandron brand. For more...
Areas of interest
